TrialThe Lancet. Haematology2015

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Paul G Richardson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.